The plasminogen activator/plasmin system.

proteases and inhibitors has been shown to be under the control of hormones and growth factors. Plasminogen activators (PAs) and their inhibitors (PAIs) are thought to be key participants in the balance ofproteolytic and antiproteolytic activities that regulates matrix turnover. This article summarizes the evidence that supports this contention, discusses the role ofPAspecific cell surface binding sites, and also draws attention to a number of instances in which the presence ofPAs cannot be reconciled with an exclusive function in ECM degradation.

[1]  J. Saurat,et al.  Differential protease expression by cutaneous squamous and basal cell carcinomas. , 1991, The Journal of clinical investigation.

[2]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[3]  L. Orci,et al.  Plasminogen activator inhibitor-1 is induced in microvascular endothelial cells by a chondrocyte-derived transforming growth factor-beta. , 1991, Biochemical and biophysical research communications.

[4]  J. Calvete,et al.  Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). , 1991, The Journal of biological chemistry.

[5]  D. Belin,et al.  Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. , 1991, The Journal of clinical investigation.

[6]  H. Chapman,et al.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. , 1991, The Journal of clinical investigation.

[7]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[8]  K. Preissner,et al.  Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. , 1991, Biochemistry.

[9]  P. Gaffney,et al.  Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. , 1991, Biochemistry.

[10]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[11]  L. Orci,et al.  Chondrocytes inhibit endothelial sprout formation in vitro: Evidence for involvement of a transforming growth factor‐beta , 1991, Journal of cellular physiology.

[12]  A. Vaheri,et al.  Plasminogen activation at the cell surface-matrix interface. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[13]  J. Quigley,et al.  Serine protease and metallo protease cascade systems involved in pericellular proteolysis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[14]  R. Montesano,et al.  Proteolytic balance and capillary morphogenesis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[15]  L. Lund,et al.  The urokinase receptor and regulation of cell surface plasminogen activation. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[16]  J. Mimuro,et al.  Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[17]  E. Plow,et al.  Plasminogen receptors in the mediation of pericellular proteolysis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[18]  P. Dennis,et al.  Growth factor control of extracellular proteolysis. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[19]  P. Rørth,et al.  Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. , 1990, Nucleic acids research.

[20]  R. Medcalf,et al.  A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP. , 1990, The Journal of biological chemistry.

[21]  L. Orci,et al.  Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro , 1990, The Journal of cell biology.

[22]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[23]  K. Danø,et al.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. , 1990, The Journal of biological chemistry.

[24]  W. Fiers,et al.  Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. , 1990, Blood.

[25]  D. von der Ahe,et al.  Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: a role of protein phosphorylation. , 1990, Nucleic acids research.

[26]  K. Hajjar,et al.  Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. , 1990, The Journal of biological chemistry.

[27]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[28]  T. V. van Berkel,et al.  Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. , 1990, Thrombosis research. Supplement.

[29]  Disease,et al.  Serine Proteases and Their Serpin Inhibitors in the Nervous System , 1990, NATO ASI Series.

[30]  D. Belin,et al.  Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. , 1989, The EMBO journal.

[31]  D. Belin,et al.  Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos , 1989, The Journal of cell biology.

[32]  N. Seeds,et al.  Characterization of 125I-tissue plasminogen activator binding to cerebellar granule neurons , 1989, The Journal of cell biology.

[33]  A. Eisen,et al.  Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Scully,et al.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. , 1989, The Journal of biological chemistry.

[35]  D. Belin,et al.  Characterization of the cellular binding site for the urokinase-type plasminogen activator. , 1989, The Journal of biological chemistry.

[36]  A. Hsueh,et al.  Suppression of ovulation rate by antibodies to tissue-type plasminogen activator and alpha 2-antiplasmin. , 1989, Endocrinology.

[37]  L. Ossowski,et al.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.

[38]  J. Sambrook,et al.  Variants of human tissue‐type plasminogen activator that lack specific structural domains of the heavy chain. , 1988, The EMBO journal.

[39]  L. Lund,et al.  One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. , 1988, The Journal of biological chemistry.

[40]  D. Belin,et al.  Meiotic maturation of mouse oocytes triggers the translation and polyadenylation of dormant tissue-type plasminogen activator mRNA. , 1987, Genes & development.

[41]  D. Belin,et al.  Modulations of functional activity in differentiated macrophages are accompanied by early and transient increase or decrease in c-fos gene transcription. , 1987, Journal of immunology.

[42]  D. Belin,et al.  Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface , 1987, The Journal of cell biology.

[43]  L. Ossowski,et al.  Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis , 1986, The Journal of experimental medicine.

[44]  S. Strickland,et al.  Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. , 1986, Biochemistry.

[45]  D. Belin,et al.  Plasminogen activator in mouse and rat oocytes: Induction during meiotic maturation , 1985, Cell.

[46]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[47]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[48]  K. Danø,et al.  Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse , 1984, The Journal of cell biology.

[49]  D. Rifkin,et al.  Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Valinsky,et al.  Plasminogen activator in the bursa of Fabricius: Correlations with morphogenetic remodeling and cell migrations , 1981, Cell.